{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:06:31Z","timestamp":1791111991743,"version":"4.1.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Curcumin (diferuloylmethane), a polyphenol natural product of the plant Curcuma longa, is undergoing early clinical trials as a novel anticancer agent. However, the anticancer mechanism of curcumin remains to be elucidated. Recently, we have shown that curcumin inhibits phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), two downstream effector molecules of the mammalian target of rapamycin complex 1 (mTORC1) in numerous cancer cell lines. This study was designed to elucidate the underlying mechanism. We observed that curcumin inhibited mTORC1 signaling not by inhibition of the upstream kinases, such as insulin-like growth factor 1 receptor (IGF-IR) and phosphoinositide-dependent kinase 1 (PDK1). Further, we found that curcumin inhibited mTORC1 signaling independently of protein phosphatase 2A (PP2A) or AMP-activated protein kinase AMPK-tuberous sclerosis complex (TSC). This is evidenced by the findings that curcumin was able to inhibit phosphorylation of S6K1 and 4E-BP1 in the cells pretreated with PP2A inhibitor (okadaic acid) or AMPK inhibitor (compound C), or in the cells expressing dominant-negative (dn) PP2A, shRNA to PP2A-A subunit, or dn-AMPK\u03b1. Curcumin did not alter the TSC1\/2 interaction. Knockout of TSC2 did not affect curcumin inhibition of mTOR signaling. Finally, we identified that curcumin was able to dissociate raptor from mTOR, leading to inhibition of mTORC1 activity. Therefore, our data indicate that curcumin may represent a new class of mTOR inhibitor. [Cancer Res 2009;69(3):1000\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2367","type":"journal-article","created":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T04:55:08Z","timestamp":1233118508000},"page":"1000-1008","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":170,"title":["Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor Complex"],"prefix":"10.1158","volume":"69","author":[{"given":"Christopher S.","family":"Beevers","sequence":"first","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.G.","family":"Webster","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of California, San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shile","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology and"},{"name":"2Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"2022061701380352000_B1","doi-asserted-by":"crossref","unstructured":"Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell\u20082007; 12: 9\u201322.","DOI":"10.1016\/j.ccr.2007.05.008"},{"key":"2022061701380352000_B2","doi-asserted-by":"crossref","unstructured":"Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell\u20082002; 110: 177\u201389.","DOI":"10.1016\/S0092-8674(02)00833-4"},{"key":"2022061701380352000_B3","doi-asserted-by":"crossref","unstructured":"Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell\u20082002; 110: 163\u201375.","DOI":"10.1016\/S0092-8674(02)00808-5"},{"key":"2022061701380352000_B4","doi-asserted-by":"crossref","unstructured":"Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell\u20082002; 10: 457\u201368.","DOI":"10.1016\/S1097-2765(02)00636-6"},{"key":"2022061701380352000_B5","doi-asserted-by":"crossref","unstructured":"Kim DH, Sarbassov DD, Ali SM, et al. G\u03b2L, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell\u20082003; 11: 895\u2013904.","DOI":"10.1016\/S1097-2765(03)00114-X"},{"key":"2022061701380352000_B6","doi-asserted-by":"crossref","unstructured":"Fonseca BD, Smith EM, Lee VH, Mackintosh C, Proud CG. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem\u20082007; 282: 24514\u201324.","DOI":"10.1074\/jbc.M704406200"},{"key":"2022061701380352000_B7","doi-asserted-by":"crossref","unstructured":"Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell\u20082007; 25: 903\u201315.","DOI":"10.1016\/j.molcel.2007.03.003"},{"key":"2022061701380352000_B8","doi-asserted-by":"crossref","unstructured":"Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt\/PKB substrate PRAS40. Nat Cell Biol\u20082007; 9: 316\u201323.","DOI":"10.1038\/ncb1547"},{"key":"2022061701380352000_B9","doi-asserted-by":"crossref","unstructured":"Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol\u20082004; 6: 1122\u20138.","DOI":"10.1038\/ncb1183"},{"key":"2022061701380352000_B10","doi-asserted-by":"crossref","unstructured":"Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol\u20082004; 14: 1296\u2013302.","DOI":"10.1016\/j.cub.2004.06.054"},{"key":"2022061701380352000_B11","doi-asserted-by":"crossref","unstructured":"Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt\/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol\u20082006; 16: 1865\u201370.","DOI":"10.1016\/j.cub.2006.08.001"},{"key":"2022061701380352000_B12","doi-asserted-by":"crossref","unstructured":"Jacinto E, Facchinetti V, Liu D, et al. SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell\u20082006; 127: 125\u201337.","DOI":"10.1016\/j.cell.2006.08.033"},{"key":"2022061701380352000_B13","doi-asserted-by":"crossref","unstructured":"Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev\u20082006; 20: 2820\u201332.","DOI":"10.1101\/gad.1461206"},{"key":"2022061701380352000_B14","doi-asserted-by":"crossref","unstructured":"Pearce LR, Huang X, Boudeau J, et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J\u20082007; 405: 513\u201322.","DOI":"10.1042\/BJ20070540"},{"key":"2022061701380352000_B15","doi-asserted-by":"crossref","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science\u20082005; 307: 1098\u2013101.","DOI":"10.1126\/science.1106148"},{"key":"2022061701380352000_B16","doi-asserted-by":"crossref","unstructured":"Gao X, Zhang Y, Arrazola P, et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol\u20082002; 4: 699\u2013704.","DOI":"10.1038\/ncb847"},{"key":"2022061701380352000_B17","doi-asserted-by":"crossref","unstructured":"Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol\u20082002; 4: 648\u201357.","DOI":"10.1038\/ncb839"},{"key":"2022061701380352000_B18","doi-asserted-by":"crossref","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol Cell\u20082002; 10: 151\u201362.","DOI":"10.1016\/S1097-2765(02)00568-3"},{"key":"2022061701380352000_B19","doi-asserted-by":"crossref","unstructured":"Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A\u20082002; 99: 13571\u201376.","DOI":"10.1073\/pnas.202476899"},{"key":"2022061701380352000_B20","doi-asserted-by":"crossref","unstructured":"Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell\u20082003; 115: 577\u201390.","DOI":"10.1016\/S0092-8674(03)00929-2"},{"key":"2022061701380352000_B21","doi-asserted-by":"crossref","unstructured":"Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev\u20082004; 18: 1533\u20138.","DOI":"10.1101\/gad.1199104"},{"key":"2022061701380352000_B22","doi-asserted-by":"crossref","unstructured":"Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A\u20082004; 101: 3329\u201335.","DOI":"10.1073\/pnas.0308061100"},{"key":"2022061701380352000_B23","doi-asserted-by":"crossref","unstructured":"Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell\u20082003; 11: 1457\u201366.","DOI":"10.1016\/S1097-2765(03)00220-X"},{"key":"2022061701380352000_B24","doi-asserted-by":"crossref","unstructured":"Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev\u20082003; 17: 1829\u201334.","DOI":"10.1101\/gad.1110003"},{"key":"2022061701380352000_B25","doi-asserted-by":"crossref","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol\u20082003; 13: 1259\u201368.","DOI":"10.1016\/S0960-9822(03)00506-2"},{"key":"2022061701380352000_B26","doi-asserted-by":"crossref","unstructured":"Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol\u20082003; 5: 578\u201381.","DOI":"10.1038\/ncb999"},{"key":"2022061701380352000_B27","doi-asserted-by":"crossref","unstructured":"Li Y, Inoki K, Guan KL. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol\u20082004; 24: 7965\u201375.","DOI":"10.1128\/MCB.24.18.7965-7975.2004"},{"key":"2022061701380352000_B28","doi-asserted-by":"crossref","unstructured":"Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol\u20082005; 15: 702\u201313.","DOI":"10.1016\/j.cub.2005.02.053"},{"key":"2022061701380352000_B29","doi-asserted-by":"crossref","unstructured":"Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science\u20082001; 294: 1102\u20135.","DOI":"10.1126\/science.1063518"},{"key":"2022061701380352000_B30","doi-asserted-by":"crossref","unstructured":"Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science\u20082001; 294: 1942\u20135.","DOI":"10.1126\/science.1066015"},{"key":"2022061701380352000_B31","doi-asserted-by":"crossref","unstructured":"Mothe-Satney I, Brunn GJ, McMahon LP, Capaldo CT, Abraham RT, Lawrence JC, Jr. Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S\/T)P sites detected by phospho-specific antibodies. J Biol Chem\u20082000; 275: 33836\u201343.","DOI":"10.1074\/jbc.M006005200"},{"key":"2022061701380352000_B32","doi-asserted-by":"crossref","unstructured":"Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev\u20082001; 15: 2852\u201364.","DOI":"10.1101\/gad.912401"},{"key":"2022061701380352000_B33","doi-asserted-by":"crossref","unstructured":"Dennis PB, Pullen N, Kozma SC, Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol\u20081996; 16: 6242\u201351.","DOI":"10.1128\/MCB.16.11.6242"},{"key":"2022061701380352000_B34","doi-asserted-by":"crossref","unstructured":"Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A\u20081999; 96: 4438\u201342.","DOI":"10.1073\/pnas.96.8.4438"},{"key":"2022061701380352000_B35","unstructured":"Aggarwal BB, Kumar A, Bharti A. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res\u20082003; 23: 363\u201398."},{"key":"2022061701380352000_B36","doi-asserted-by":"crossref","unstructured":"Singh S. From exotic spice to modern drug? Cell\u20082007; 130: 765\u20138.","DOI":"10.1016\/j.cell.2007.08.024"},{"key":"2022061701380352000_B37","doi-asserted-by":"crossref","unstructured":"Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer\u20082006; 119: 757\u201364.","DOI":"10.1002\/ijc.21932"},{"key":"2022061701380352000_B38","doi-asserted-by":"crossref","unstructured":"Evans DR, Myles T, Hofsteenge J, Hemmings BA. Functional expression of human PP2Ac in yeast permits the identification of novel C-terminal and dominant-negative mutant forms. J Biol Chem\u20081999; 274: 24038\u201346.","DOI":"10.1074\/jbc.274.34.24038"},{"key":"2022061701380352000_B39","doi-asserted-by":"crossref","unstructured":"Lu M, Tang Q, Olefsky JM, Mellon PL, Webster NJ. Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in L\u03b2T2 gonadotropes. Mol Endocrinol\u20082008; 22: 760\u201371.","DOI":"10.1210\/me.2007-0330"},{"key":"2022061701380352000_B40","doi-asserted-by":"crossref","unstructured":"Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene\u20082006; 25: 7029\u201340.","DOI":"10.1038\/sj.onc.1209691"},{"key":"2022061701380352000_B41","doi-asserted-by":"crossref","unstructured":"Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem\u20082000; 275: 7416\u201323.","DOI":"10.1074\/jbc.275.10.7416"},{"key":"2022061701380352000_B42","doi-asserted-by":"crossref","unstructured":"Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem\u20082005; 280: 25485\u201390.","DOI":"10.1074\/jbc.M501707200"},{"key":"2022061701380352000_B43","doi-asserted-by":"crossref","unstructured":"Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev\u20082005; 15: 34\u201341.","DOI":"10.1016\/j.gde.2004.12.004"},{"key":"2022061701380352000_B44","doi-asserted-by":"crossref","unstructured":"Hardie DG, Haystead TA, Sim AT. Use of okadaic acid to inhibit protein phosphatases in intact cells. Methods Enzymol\u20081991; 201: 469\u201376.","DOI":"10.1016\/0076-6879(91)01042-Z"},{"key":"2022061701380352000_B45","doi-asserted-by":"crossref","unstructured":"Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J\u20082008; 22: 954\u201365.","DOI":"10.1096\/fj.06-7859rev"},{"key":"2022061701380352000_B46","doi-asserted-by":"crossref","unstructured":"Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR. J Clin Invest\u20082007; 117: 730\u20138.","DOI":"10.1172\/JCI28984"},{"key":"2022061701380352000_B47","doi-asserted-by":"crossref","unstructured":"Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol\u20082007; 72: 29\u201339.","DOI":"10.1124\/mol.106.033167"},{"key":"2022061701380352000_B48","doi-asserted-by":"crossref","unstructured":"Li M, Zhang Z, Hill DL, Wang H, Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K\/mTOR\/ETS2 pathway. Cancer Res\u20082007; 67: 1988\u201396.","DOI":"10.1158\/0008-5472.CAN-06-3066"},{"key":"2022061701380352000_B49","doi-asserted-by":"crossref","unstructured":"Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt\/mTOR\/p70S6K and ERK1\/2 signaling pathways in curcumin-induced autophagy. Autophagy\u20082007; 3: 635\u20137.","DOI":"10.4161\/auto.4916"},{"key":"2022061701380352000_B50","doi-asserted-by":"crossref","unstructured":"Sarbassov DD, Sabatini DM. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem\u20082005; 280: 39505\u20139.","DOI":"10.1074\/jbc.M506096200"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/3\/1000\/2621967\/1000.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/3\/1000\/2621967\/1000.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T08:33:53Z","timestamp":1655454833000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/3\/1000\/552880\/Curcumin-Disrupts-the-Mammalian-Target-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,29]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,1,29]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2367","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,29]]}}}